Flinton Capital Management LLC grew its position in Eli Lilly and Co (NYSE:LLY) by 35.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 51,408 shares of the company’s stock after purchasing an additional 13,566 shares during the quarter. Flinton Capital Management LLC’s holdings in Eli Lilly and were worth $4,342,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Candriam Luxembourg S.C.A. grew its position in Eli Lilly and by 166.7% during the third quarter. Candriam Luxembourg S.C.A. now owns 430,424 shares of the company’s stock worth $36,818,000 after buying an additional 269,038 shares in the last quarter. Chevy Chase Trust Holdings Inc. grew its position in Eli Lilly and by 1.0% during the third quarter. Chevy Chase Trust Holdings Inc. now owns 851,985 shares of the company’s stock worth $72,879,000 after buying an additional 8,328 shares in the last quarter. Exane Derivatives grew its position in Eli Lilly and by 2,838.2% during the fourth quarter. Exane Derivatives now owns 18,687 shares of the company’s stock worth $1,578,000 after buying an additional 18,051 shares in the last quarter. BARING ASSET MANAGEMENT Ltd grew its position in Eli Lilly and by 114.6% during the third quarter. BARING ASSET MANAGEMENT Ltd now owns 43,492 shares of the company’s stock worth $3,721,000 after buying an additional 23,229 shares in the last quarter. Finally, Bank of the Ozarks grew its position in Eli Lilly and by 18.0% during the third quarter. Bank of the Ozarks now owns 10,068 shares of the company’s stock worth $861,000 after buying an additional 1,535 shares in the last quarter. 77.63% of the stock is currently owned by institutional investors.
Shares of Eli Lilly and stock opened at $76.85 on Friday. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.32 and a quick ratio of 1.01. Eli Lilly and Co has a 1-year low of $73.69 and a 1-year high of $89.09. The stock has a market cap of $86,113.99, a price-to-earnings ratio of 17.96, a price-to-earnings-growth ratio of 1.43 and a beta of 0.26.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The firm had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $5.93 billion. During the same period last year, the business posted $0.95 EPS. The business’s revenue was up 7.0% compared to the same quarter last year. sell-side analysts forecast that Eli Lilly and Co will post 4.87 earnings per share for the current year.
LLY has been the topic of a number of analyst reports. Jefferies Group set a $93.00 price target on Eli Lilly and and gave the stock a “buy” rating in a research report on Monday, February 26th. Goldman Sachs downgraded Eli Lilly and from a “buy” rating to a “neutral” rating and increased their price target for the stock from $86.98 to $95.00 in a research report on Tuesday, January 16th. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $85.00 price target on the stock in a research report on Tuesday. Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and raised their target price for the company from $85.52 to $115.00 in a report on Friday, January 5th. Finally, Bank of America reduced their target price on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a report on Thursday, February 1st. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $92.84.
In other Eli Lilly and news, SVP Jeffrey N. Simmons sold 9,625 shares of the stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $81.12, for a total transaction of $780,780.00. Following the completion of the sale, the senior vice president now directly owns 152,120 shares in the company, valued at approximately $12,339,974.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.09, for a total value of $72,981.00. Following the completion of the sale, the insider now owns 4,130 shares of the company’s stock, valued at $334,901.70. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 15,261 shares of company stock valued at $1,225,085. Company insiders own 0.11% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Flinton Capital Management LLC Has $4.34 Million Holdings in Eli Lilly and Co (LLY)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/07/flinton-capital-management-llc-boosts-stake-in-eli-lilly-and-co-lly.html.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.